Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Inc. is a U.S.-based biopharmaceutical company that develops and commercializes prescription medicines for neurological, sleep, psychiatric, and other specialty disease areas. Its portfolio includes marketed products such as Fanapt, HETLIOZ, PONVORY, and NERES, alongside a pipeline of additional indications and new drug candidates.
Tilikausi 2025 · muutos edellisvuodesta
Kehitys 2020–2025
Liiketoiminta
Osuus liikevaihdostaApproved prescription medicines sold in the U.S. and select international markets.
HETLIOZ-based therapies for Non-24, SMS, and related sleep indications.
Fanapt and related programs for schizophrenia, bipolar disorder, and depression.
PONVORY and pipeline assets for multiple sclerosis and inflammatory diseases.
Earlier-stage candidates across rare disease, GI, dermatology, and oncology.
Tuotteet
Raportoitu · osuus liikevaihdosta- Fanapt54,3 %
- Hetlioz33,1 %
- PONVORY12,7 %
Lähde: 10-K FY2025, yhtiön tuotelinjoittain raportoima liikevaihto (SEC XBRL). Osuudet on laskettu näytetyistä riveistä ja ne summautuvat 100 %:iin.
Asiakkaat
Vanda sells primarily to a limited number of U.S. pharmaceutical wholesalers, specialty pharmacies, and specialty distributors that then supply patients through the prescription channel. Demand is ultimately driven by physicians, patients, and third-party payors in specialty therapeutic areas, with reimbursement and formulary access playing a central role in uptake. Outside the U.S., the company also works through distribution partners in selected markets such as Israel and Germany.
Buy Fanapt and other products for broad downstream distribution in the retail channel.
Dispense HETLIOZ and other specialty medicines to patients under restricted distribution.
Handle PONVORY fulfillment and inventory flow in the specialty prescription channel.
Distribute selected products such as Fanapt in Israel and HETLIOZ in Germany.
End users and decision makers whose diagnosis, prescribing, and adherence drive demand.
Strategia
Vanda’s strategy centers on maximizing the commercial performance of its marketed products while expanding them into additional indications and geographies. It also seeks to advance a pipeline built around genetics, genomics, and novel mechanisms, using both internal development and external licensing to broaden its future product base.
Current products fund the business and support the company’s commercial infrastructure.
Additional indications can extend product life cycles and broaden addressable markets.
New molecular assets reduce dependence on a small number of marketed products.
Maantiede
Vanda is headquartered in Washington, D.C. and commercializes its products primarily in the United States. It also has limited international activity through distribution of Fanapt in Israel and sales of HETLIOZ in Germany, which adds some geographic diversification but leaves the business largely U.S.-centric.
Riskit
Vanda depends on a small number of commercial products and a concentrated set of customers, so sales can be volatile and sensitive to inventory buying patterns, reimbursement, and generic competition. The company also faces patent litigation, regulatory risk, and clinical development uncertainty, all of which can affect product exclusivity, approvals, and future revenue streams.
- Generic competition for HETLIOZ and other productsVaikutus: KorkeaTodennäköisyys: Korkea
Loss of exclusivity can materially reduce U.S. sales and market share.
Kohdistuu: HETLIOZ
- Patent and IP litigationVaikutus: KorkeaTodennäköisyys: Korkea
Enforcement and defense of patents consume resources and may not preserve exclusivity.
Kohdistuu: HETLIOZ and other branded products
- Customer concentrationVaikutus: KorkeaTodennäköisyys: Kohtalainen
A limited number of wholesalers and specialty pharmacies can drive quarter-to-quarter volatility.
Kohdistuu - Regulatory and clinical development riskVaikutus: KeskitasoTodennäköisyys: Kohtalainen
Pipeline programs may fail in trials or be delayed by regulators.
Kohdistuu - Reimbursement and pricing pressureVaikutus: KeskitasoTodennäköisyys: Kohtalainen
Specialty drug demand depends on payor coverage and favorable reimbursement.
Kohdistuu: U.S. commercial portfolio
Kirjanpito
Harkinnanvaraiset erätRebates, chargebacks, co-pay assistance, and returns reduce net sales and require judgment.
Vaikutus: Can materially affect quarterly revenue and gross-to-net trends
Sales are recognized when product is delivered to the customer, not when prescribed.
Vaikutus: Timing of wholesaler and specialty pharmacy orders affects period results
Revenue and receivables are concentrated with a small customer base.
Vaikutus: Bad-debt assumptions can move operating results
Management must assess whether future taxable income supports tax assets.
Vaikutus: Can create large non-cash swings in reported tax expense
License agreements can create accrued or future milestone payments.
Vaikutus: Affects liabilities and operating cash flow timing
Samankaltaisia listattuja yhtiöitä
Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.
NRX Pharmaceuticals, Inc.
NRXP · Pharmaceutical Preparations
MediciNova, Inc
MNOV · Pharmaceutical Preparations
MedicNova Inc.
Definium Therapeutics, Inc.
DFTX · Medicinal Chemicals & Botanical Products
Teva Pharmaceutical Industries Limited
TEVA · Pharmaceutical Preparations
Firefly Neuroscience, Inc
AIFF · Services-Prepackaged Software
Vistagen Therapeutics, Inc.
VTGN · Pharmaceutical Preparations
Vistagen Therapeutics is a U.S.-based clinical-stage biopharmaceutical company focused on neuroscience disorders.
Päivitetty: 24.9.2026